pp-1

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

SLU-PP-1072 is an ERRα and ERRγ inverse dual agonist that disrupts PCa cell metabolism and induces apoptosis through cell cycle dysregulation.SLU-PP-1072 is used to study prostate cancer (PCa).

THPP-1 is a potent and orally bioavailable inhibitor of PDE10A(Ki of 1 nM and 1.3 nM for human and rat PDE10A, respectively).

Enpp-1-IN-22 is a potent oral bioavailable prodrug of the ENPP1 inhibitor dimeric paraformaldehyde ester, exhibiting anticancer activity.

Enpp-1-IN-23 (compound 27) is an Enpp-1 inhibitor with an IC50 value of 1.2 nM. This compound is utilized in cancer research.

Enpp-1-IN-24 (compound 7) is an ENPP1 inhibitor that, when used in combination with anti-PD-1 antibodies, achieves a tumor growth inhibition rate of 77.7% and enhances survival rates in a mouse model.

Enpp-1-IN-21 (compound 4g) is an inhibitor of ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1), with IC50 values of 0.45 μM for ENPP1 and 0.19 μM for ENPP3.

Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.

CPP-115 is a GABA-aminotransferase inhibitor and a high-affinity vigabatrin analogue.

Enpp-1-IN-14 is a potent inhibitor of Ectonucleotide Pyrophosphatase Phosphodiesterase-1 (ENPP1) with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity.

Enpp-1-IN-10 (compound 1) is a potent inhibitor of Ecto-nucleotide pyrophosphatase phosphodiesterases 1 (ENPP1) with a Ki value of 3.866 μM, suitable for anticancer research [1].

Enpp-1-IN-11 (compound 23) is a highly potent inhibitor of Ecto-nucleotide pyrophosphatase phosphodiesterases 1 (ENPP1), with a Ki value of 45 nM. It demonstrates excellent stability in human and mouse plasma and exhibits low clearance in both human and mouse liver microsomes, holding promise for anticancer research [1].

Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) with a K_i of 41 nM, exhibits anti-tumor activity [1].

Enpp-1-IN-9, a powerful inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1), exhibits wide substrate specificity, capable of cleaving various bonds such as phosphodiester bonds of nucleotides and nucleotide sugars, as well as pyrophosphate bonds of nucleotides and nucleotide sugars. Its potential application lies in the fields of cancer and infectious disease research[1].

Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which exhibits broad specificity, capable of cleaving phosphodiester bonds of nucleotides and nucleotides, as well as pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-5 has potential applications in cancer and infectious disease research.

Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential for cancer disease studies.

Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which has broad specificity and cleaves a wide range of substrates, including phosphodiester bonds and pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-7 has potential applications in cancer and infectious disease research.

Enpp-1-IN-8 is a potent ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitor with broad specificity, capable of cleaving a wide range of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. Enpp-1-IN-8 shows potential for cancer and infectious disease studies.

Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential applications in cancer and infectious disease research.

Enpp-1-IN-13 is an ectonucleotide pyrophosphatase phosphodiesterase (ENPP) inhibitor that is able to act on ENPP1 (IC50: 1.29 μM) and ENPP3 (IC50: 20.2 μM), exhibiting anticancer effects.

NEPP-11 is a selective JNK signaling pathway inhibitor.

Compound 88a (Enpp-1-IN-15) is an inhibitor of Ectonucleotide Pyrophosphatase Phosphodiesterase 1 (Enpp-1), exhibiting a Ki value of 0.00586 nM [1].

TPP-1, a potent inhibitor of the PD-1 PD-L1 interaction, exhibits high affinity for PD-L1, with a dissociation constant (K D) of 95 nM. It effectively inhibits human tumor growth in vivo by reactivating T-cell function [1].

TPP-1 TFA, a potent inhibitor of the PD-1 PD-L1 interaction, selectively binds to PD-L1 with high affinity (K D =95 nM). It effectively inhibits human tumor growth in vivo by reactivating T-cell function [1].